-
Mashup Score: 1Wolters Kluwer Health - 10 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Longitudinal Effects of Elexacaftor/Tezacaftor/Ivacaftor on Sputum Viscoelastic Properties, Airway Infection and Inflammation in Patients with Cystic Fibrosis - 10 month(s) ago
Background Recent studies demonstrated that the triple combination CFTR modulator therapy elexacaftor/tezacaftor/ivacaftor (ETI) improves lung function and reduces pulmonary exacerbations in CF patients with at least one F508del allele. However, effects of ETI on downstream consequences of CFTR dysfunction, i.e. abnormal viscoelastic properties of airway mucus, chronic airway infection and…
Source: European Respiratory SocietyCategories: General Medicine News, Latest HeadlinesTweet-
Triple #combinationtherapy brings lasting improvement in #cysticfibrosis, shows study https://t.co/MJow935Uc4 https://t.co/9S94FTXVii
-
-
Mashup Score: 3Treatment Selection Considerations for Mild to Moderate Acne - 1 year(s) ago
Dr Hilary Baldwin discusses her treatment considerations and approach in the management of patients with mild to moderate acne, highlighting the benefit of combination therapy.
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet-
Dr Hilary Baldwin discusses her treatment considerations and approach in the management of patients with mild to moderate #acne, highlighting the benefit of #combinationtherapy in this episode of The Changing Faces of Acne, a #FrontLine Forum series. https://t.co/x4OCpkXibf
-
-
Mashup Score: 1Treatment Selection Considerations for Mild to Moderate Acne - 1 year(s) ago
Dr Hilary Baldwin discusses her treatment considerations and approach in the management of patients with mild to moderate acne, highlighting the benefit of combination therapy.
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet-
In this #FrontlineForum episode, Dr Hilary Baldwin discusses her treatment considerations and approach in the management of patients with mild to moderate #acne, highlighting the benefit of #combinationtherapy. https://t.co/F7j0q2yITf
-
-
Mashup Score: 2In vivo self-assembled siRNA as a modality for combination therapy of ulcerative colitis - Nature Communications - 2 year(s) ago
Management of ulcerative colitis can require a combination of treatments targeting different pathways. Here the authors design a therapy for ulcerative colitis based on a multitargeted genetic circuit to simultaneously target TNF-α, B7-1 and integrin α4, and show the therapy is effective in male mice with induced or spontaneous genetic colitis.
Source: NatureCategories: General Medicine News, Latest HeadlinesTweet-
In vivo self-assembled siRNA as a modality for #combinationtherapy of #ulcerativecolitis @NatureComms https://t.co/3PJlueJN0K https://t.co/DCePa2NnsT
-
-
Mashup Score: 0Talazoparib Plus Avelumab in Recurrent Mismatch Repair–Proficient Endometrial Cancer - The ASCO Post - 2 year(s) ago
By Matthew Stenger Posted: 8/4/2022 12:06:00 PM Last Updated: 8/4/2022 11:28:21 AM In a phase II trial reported in JAMA Oncology, Konstantinopoulos et al found that the combination of talazoparib and avelumab was active in patients with recurrent mismatch repair–proficient endometrial cancer. Study…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Talazoparib Plus Avelumab in Recurrent Mismatch Repair–Proficient Endometrial Cancer https://t.co/JKlYCJayQG #gyncsm #EndometrialCancer #oncology #immunotherapy #CombinationTherapy
-
-
Mashup Score: 3New combination therapy exploits ‘natural killer’ cells to destroy head and neck tumours - 2 year(s) ago
Scientists have identified a new treatment combination that is highly effective at suppressing the growth of head and neck tumours.
Source: www.icr.ac.ukCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📢NEWS: Scientists at the ICR have identified a new #CombinationTherapy that is highly effective at suppressing tumour growth in #HeadAndNeckCancer. This could allow more patients with this type of cancer to benefit from #Immunotherapy. Read more 👇 https://t.co/8Gm6vSd2qI https://t.co/RNRGqKA46I
-
-
Mashup Score: 4
A total of 150 people took part in the trial.
Source: The IndependentCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📰 More promising clinical trial results for a #CombinationTherapy using capivasertib - this time in #ProstateCancer. 💡Capivasertib was discovered following collaborative work by the ICR and partners Astex Pharmaceuticals and AstraZeneca. https://t.co/oGtH3cyLRv
-
-
Mashup Score: 1PM - 08/06/2022 - BBC Sounds - 2 year(s) ago
Afternoon news and current affairs programme
Source: BBCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Yesterday on @BBCRadio4's PM programme, Professor Alan Melcher shared more on an early trial of an MRNA vaccine #CombinationTherapy that's showing promise against #PancreaticCancer. The results of the study were presented at #ASCO22. Listen from 20:10. https://t.co/QfdsdJaC12
-
-
Mashup Score: 6
A drug combination targeting multiple mutant versions of cancer’s ‘death star’ protein has shown promise in a small, early-phase clinical trial for some patients with advanced lung, ovarian and thyroid cancer.
Source: www.icr.ac.ukCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Rather than drugging #KRAS itself, the new dual #CombinationTherapy renders KRAS less effective by simultaneously blocking the two pathways that KRAS relies upon to drive #Cancer growth 👇 https://t.co/tLTgcmthbO #UnlockTreatments #ASCO22 https://t.co/Fo8HbAyvOk
-
Novel #combinationtherapy using selinexor and ruxolitinib in patients with treatment-naive #myelofibrosis shows incredible promise. About 78% achieved 50% or better improvement in myelofibrosis symptoms. https://t.co/0Qx9WeXkaI https://t.co/g1KmNNPR57